Spark Therapeutics reported $80.2 million, or $2.15 per share, net income in the second quarter of 2018, compared to a net loss of $74.4 million, or $2.40 per share, in the second quarter of 2017.
Selling, general and administrative expenses increased from $26.7 million in 2017’s second quarter to $29.7 million in 2018’s second quarter, an increase the company attributed to increases in salaries and related costs supporting the launch of Luxturna.
Research and development costs for the quarter decreased by $7.5 million compared with the same quarter in 2017, (Read more...)
Uncategorized